New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
After menin, the company tries again with farnesyl transferase.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
The companies clash over survival curve similarities – and differences.
Petosemtamab's phase 2 data in this setting should come by the year end.
After ZW171's exit, ZW251 enters the clinic.
